TQM13

TQM13 is a recombinant protein derivative of interleukin-13 (IL-13) engineered with four specific mutations (E13K, R66D, S69D, and K105R) to selectively target the tumor-restricted biomarker IL13Rα2. Developed by researchers at Wake Forest University, TQM13 is designed to have high affinity for IL13Rα2, which is overexpressed in glioblastoma multiforme (GBM) and other cancers, while lacking binding affinity for the physiologically ubiquitous IL13Rα1/IL4Rα heterodimer. This selectivity aims to minimize off-target effects in normal tissues. TQM13 has been investigated as a delivery vehicle for diagnostic and therapeutic agents, such as radionuclides, to treat heterogeneous tumors like GBM. Preclinical studies have demonstrated its ability to bind specifically to IL13Rα2-expressing tumors in vivo, making it a potential candidate for targeted therapy in GBM and other IL13Rα2-positive malignancies.

Other names

IL13Rα2-Targeted Quadruple Mutant of IL-13IL-13 quadruple mutantIL13 quadruple mutantIL 13 quadruple mutant